Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

378P - MGMT status influences prognosis of patients with IDH wild type grade III gliomas

Date

17 Sep 2020

Session

E-Poster Display

Topics

Tumour Site

Central Nervous System Malignancies

Presenters

Enrico Franceschi

Citation

Annals of Oncology (2020) 31 (suppl_4): S396-S408. 10.1016/annonc/annonc269

Authors

E. Franceschi1, V. Di Nunno2, A. Tosoni1, L. Gatto2, M. Di Battista2, S. Minichillo2, A. Mura2, C. Lamperini2, G. Nuvola3, M. Sisi3, M. Mosca3, S. Bartolini2, A.A. Brandes2

Author affiliations

  • 1 Department Of Medical Oncology, Azienda USL-IRCCS Institute of Neurological Sciences, 40139 - BOLOGNA/IT
  • 2 Department Of Medical Oncology, Azienda USL-IRCCS Institute of Neurological Sciences, 40139 - Bologna/IT
  • 3 Clinical Oncology, S. Orsola Malpighi Hospital - University of Bologna, 40138 - Bologna/IT

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 378P

Background

WHO grade III gliomas are classified according to the presence of IDHmutation.IDH wild type (IDH wt) is associated with poor prognosis and limited effectiveness of treatments. The aim of this study was to find out if MGMT methylation represents a prognostic factor in this setting.

Methods

We analyzed our Institutional data warehouse for all consecutive patients (pts) with newly diagnosed, histologically proven grade III, IDH wt gliomas. IDH 1/2 assessment was performed by Next Generation Sequencing (NGS). MGMT methylation was assessed by methylation specific PCR (MSP). Tissue samples were also centrally reviewed for histology.

Results

The analysis included 73 pts with grade III, IDH wt (19.3%) gliomas. Median follow-up time was 69.9 months. Median age was 50 (Range: 18-75), M/F ratio was40(54.8%)/33(45.2%),.MGMT promoter was methylated in 34 pts (46.6%) and unmethylated in 39 pts (53.4%).After surgery, 9 pts (12.3%) received RT alone, 57 pts (78.1%) received both RT and CT (sequential, concomitant or both). Median survival was 26.2 months. In multivariate analysis age (HR=1.064, 95%CI: 1.030-1.099; P<0.001) and MGMT methylation (HR=0.422, 95%CI: 0.210-0.848; P=0.015) were independently associated with risk for death.

Conclusions

IDH wild type confers a dismal prognosis in patients with grade III glioma. MGMT methylation, as was demonstrated in glioblastoma, represents a prognostic factor that correlated with a reduced risk of death. Further studies will investigate potential correlations with treatments.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.